TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)
Close on Nov 17, 2026Market cap $10.23MP/E –Yield –
TScan Therapeutics total assets
Total assets on the balance sheet at the end of each period.
TScan Therapeutics's total assets was $171.45M at Jun 30, 2026. For fiscal 2025 it was $228.79M, down 38.4% from the year before. The highest annual figure on record is $371.12M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $228.79M | -38.4% |
| FY2024 | Dec 31, 2024 | $371.12M | +36.4% |
| FY2023 | Dec 31, 2023 | $272.15M | +36.7% |
| FY2022 | Dec 31, 2022 | $199.09M | +5.8% |
| FY2021 | Dec 31, 2021 | $188.11M | +278.2% |
| FY2020 | Dec 31, 2020 | $49.74M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $171.45M | -42.6% |
| Q1 FY2026 | Mar 31, 2026 | $201.99M | -39.3% |
| Q4 FY2025 | Dec 31, 2025 | $228.79M | -38.4% |
| Q3 FY2025 | Sep 30, 2025 | $262.23M | -24.7% |
| Q2 FY2025 | Jun 30, 2025 | $298.56M | -20.4% |
| Q1 FY2025 | Mar 31, 2025 | $332.71M | +38.1% |
| Q4 FY2024 | Dec 31, 2024 | $371.12M | +36.4% |
| Q3 FY2024 | Sep 30, 2024 | $348.03M | +19.4% |
| Q2 FY2024 | Jun 30, 2024 | $374.87M | +18.3% |
| Q1 FY2024 | Mar 31, 2024 | $240.83M | +38.7% |
| Q4 FY2023 | Dec 31, 2023 | $272.15M | +36.7% |
| Q3 FY2023 | Sep 30, 2023 | $291.38M | +76.1% |
| Q2 FY2023 | Jun 30, 2023 | $316.92M | +107.9% |
| Q1 FY2023 | Mar 31, 2023 | $173.58M | +3.2% |
| Q4 FY2022 | Dec 31, 2022 | $199.09M | +5.8% |
| Q3 FY2022 | Sep 30, 2022 | $165.45M | -19.2% |
| Q2 FY2022 | Jun 30, 2022 | $152.42M | +17.2% |
| Q1 FY2022 | Mar 31, 2022 | $168.20M | +238.2% |
| Q4 FY2021 | Dec 31, 2021 | $188.11M | – |
| Q3 FY2021 | Sep 30, 2021 | $204.89M | – |
| Q2 FY2021 | Jun 30, 2021 | $130.01M | – |
| Q4 FY2020 | Dec 31, 2020 | $49.74M | – |
See a number that looks wrong?